Ann: CEO presentation to AGM, page-8

Overall the AGM was a lot like their other AMG's over past years.. Plenty of blue sky and potential there but no follow through with the SP... Chairman had some reasons for the low share price around underwriters selling on market after capital raising and also a large holder having to sell down over 10 mil recently (whether you want to believe that or not).

The main take away for me was essentially everything is coming down to the success of the clinical trial (CT) - multi nationals need independent evidence before getting involved which is specifically what the CT is designed to provide.

Everything else they are doing is basically window dressing compared to the huge impact a positive CT will have,,,, but the sting is if the CT isnt so positive i think ALT are finished. All the eggs are in the Clinical Trial basket now - all we can do is hope!